Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 11, 2026JCO oncology advances.Open Access

Prognostic Factors Influencing the Efficacy and Safety of Teclistamab and Elranatamab in Multiple Myeloma: A Multicenter Propensity-Weighted Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJérémie ZerbitGFGuillemette FouquetMDMarion Detroit

Discussion

Loading...

Member takes

Overview

Multicenter analysis reveals important efficacy and safety outcomes of bispecific antibody therapy in relapsed/refractory multiple myeloma, suggesting tailored treatment may be necessary.

Key Points

  • This analysis aims to evaluate the efficacy and safety of teclistamab and elranatamab in treating relapsed/refractory multiple myeloma.
  • Retrospective multicenter study across 10 hospitals
  • Evaluated 201 patients receiving teclistamab and elranatamab
  • Compared outcomes to a propensity score-matched historical control cohort
  • Analyzed progression-free survival, overall survival, infection rates, and adverse events.
  • Median progression-free survival was 17.9 months for BsAb cohort, with teclistamab not reached and elranatamab 9.3 months.
  • Rate of grade ≥3 infections was significantly higher in BsAb-treated patients (98.2/100 patient-years vs. 27.1/100, P < .001).
  • Teclistamab showed superior overall survival at 12 months (73.4% vs. 53.9%, P < .05).
  • Common adverse events included cytokine release syndrome (50.2%; 2% grade ≥3) and neurotoxicity (8.5%; 5.9% grade ≥3).

Cite This Study

Zerbit et al. (2026) studied this question.

synapsesocial.com/papers/69d9e66378050d08c1b76c2fhttps://doi.org/10.1200/oa-25-00077
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience.2024 · 5 citations
  2. 2Bispecific antibodies in the treatment of relapsed refractory multiple myeloma: A meta analysis.2026
  3. 3Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group2025
  4. 4Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety2026
  5. 5Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study2024 · 108 citations